Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -0.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRNX — M&A activity — Changes in Control of Registrant
Dated 2026-09-01
Changes in Control of Registrant. The disclosures set forth in the Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference. As a result of the consummation of the Merger, a change in control of the Company occurred and the Company became a wholly owned subsidiary of Parent. The aggregate consideration paid by Parent in connection with the Merger was approximately $10.0 billion, which was funded using a combination of…
Why it matters: Vertex's acquisition is important. It could change Crinetics' future. It may help PALSONIFY and atumelnant.
Supportive ifThe acquisition will close as planned in Q3 2026. It has all approvals needed.
Worry ifThe acquisition may be delayed or fail. This could happen due to regulatory or shareholder issues.
Why it matters: If the health care sector's revenue growth speeds up, it could help Crinetics. A stronger sector may lift all companies.
Supportive ifHealth care sector revenue growth increases back toward 10% or higher.
Worry ifHealth care sector revenue growth continues to slow or stays below 10%.
Why it matters: The earnings report will show financial performance and future plans.
Watch forEarnings report shows better financial results than Q1.
Also watch forThe earnings report shows more drops. It also misses expectations.
Why it matters: FDA approval would support Crinetics' plans. It would also strengthen its position in CAH treatment.
Supportive ifThe FDA grants approval for atumelnant for CAH by the end of Q4 2026.
Worry ifThe FDA delays or denies approval for atumelnant.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$48 on $10,000 · ±0.5% | How much price usually moves either way. |
| Bad day | $513 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,221 loss on $10,000 · 42.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Growing revenue will show that the product is accepted in the market.
Supportive ifPALSONIFY net product revenue exceeds $24 million in Q3 2026.
Worry ifPALSONIFY net product revenue falls below $24 million in Q3 2026.
Why it matters: More prescribers means PALSONIFY is being accepted more. This shows it is growing in the market.
Supportive ifBy Q3 2026, more than 450 healthcare providers will use PALSONIFY.
Worry ifThe prescriber count stagnates or declines from 385 in Q2 2026.
Why it matters: Leadership changes can change the company's path. Stability builds trust with investors.
Watch forA strong new hire is replacing the COO. This shows stability.
Also watch forNo new leadership news is out. This creates uncertainty about the company.
Why it matters: Keeping expenses in check is crucial for financial health. Higher costs could signal trouble.
Worry ifOperating expenses are above $520M. This shows there are cost control issues.
Less concerning ifOperating expenses are below $480M. This shows good cost management.
Why it matters: Keeping expenses low is important for the company. It helps with financial health and growth.
Supportive ifOperating expenses are between $480M and $520M. This shows good cost control.
Worry ifOperating expenses are more than $520M. This could mean issues with money management.
Why it matters: Starting this trial is important. It helps Crinetics' pipeline and meets medical needs.
Supportive ifThe pivotal Phase 2/3 trial for atumelnant begins as scheduled in Q2 2026.
Worry ifThe trial initiation is delayed beyond Q2 2026.